Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.51 |
| ▸ | GRK2 | P25098 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634723 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748823 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL594720 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748822 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL195485 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL596331 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL596330 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748197 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL596332 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748184 | 0.93 | DGAT1 (0.47) | DGAT1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317767-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2024-09-26 | — | — | US | disclosed |
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2023-07-13 | — | — | US | disclosed |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| CN-109890385-B | Crystalline forms of (1R,2R) -2- [4- (3-methyl-1H-pyrazol-5-yl) benzoyl ] -N- (4-oxo-4, 5,6, 7-tetrahydropyrazolo [1,5-a ] pyrazin-3-yl) cyclohexanecarboxamide | 阿斯利康(瑞典)有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-11-18 | — | — | US | disclosed |
| EP-3670499-B1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2021-05-11 | — | — | US | disclosed |
| EP-3670499-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | Astrazeneca AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| US-10689387-B2 | Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide | ASTRAZENECA AB (SE) | 2020-06-23 | — | — | US | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DGAT1 34/4885GRK2 666/4885CASP6 788/4885 |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | DGAT1 2/4885GRK2 1019/4885CASP6 3996/4885 |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DGAT1 34/4885GRK2 666/4885CASP6 788/4885 |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-10689387-B2 | Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide | RYR2, FABP3, RYR1 | DGAT1 2738/4885GRK2 724/4885CASP6 426/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | DGAT1 2/4885GRK2 1019/4885CASP6 3996/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | DGAT1 2/4885GRK2 1019/4885CASP6 3996/4885 |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | DGAT1 2/4885GRK2 1019/4885CASP6 3996/4885 |
| US-20240317767-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.